Tag: COVAXIN

The vaccine is priced at INR 325/dose for large volume procurement by state governments and union government

Click to Read: January 2023 Edition of BioVoice eMagazine BioVoice News, India's leading B2B news media for BioTech, HealthTech and AgriTech, is celebrating its 7th anniversary...

As per AIG study, protein-based vaccine when given as a booster shown to induce not only increased antibody response but also robust T-cell and B-cell (memory cell) response linked with long-term immunity

Dr Ella while delivering the award lecture, said there was a requirement to create an ecosystem where India should innovate and not copy from other countries and encourage start-ups

Despite receiving emergency use listing from the World Health Organization, Covaxin has not been cleared for any age group in the United States

The trials for 0.5 ml single dose of nasal vaccine will be conducted at nine locations in the country.

100% of test serum samples showed neutralization of the Delta variant and more than 90% of serum samples showed neutralization of the Omicron variant

The phase 2, double-blind, randomised controlled COVAXIN trial demonstrated long-term safety with no serious adverse events

Mix and match of different vaccines is safe and elicits robust antibody response, revealed the study conducted by AIG Hospitals The first pilot study from India analyzing COVAXIN – COVISHEILD mixed doses

Whole-Virion inactivated SARS-CoV-2 Vaccine (BBV152) has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults......................